<?xml version="1.0" encoding="UTF-8"?>
<p>In the preceding 20 years, two novel coronaviruses have been emerged mainly causing the severe acute respiratory syndrome coronavirus (SARS‐CoV) and Middle East respiratory syndrome coronavirus (MERS‐CoV) responsible for the epidemics in 2002 and 2012, respectively (World Health Organization, 
 <xref rid="tbed13734-bib-0090" ref-type="ref">2003</xref>, 
 <xref rid="tbed13734-bib-0091" ref-type="ref">2013</xref>). Since the pandemic spread of novel coronavirus (SARS‐CoV‐2) and the rapidly increasing number of patients by minutes (473,061 deaths at the time of writing this article by 24 June 2020, unfortunately), the focus has been on the assessments to recruit the existing anti‐viral compounds which must be complemented by the new drug discovery programmes in the future. Nevertheless, the current urgent demand is being addressed by the clinical trials of 31 drugs to approve the effectiveness of the existing anti‐viral drugs on SARS‐CoV‐2.
</p>
